Canada Markets open in 27 mins

Celltrion, Inc. (068270.KS)

KSE - KSE Delayed Price. Currency in KRW
Add to watchlist
213,000.00+1,500.00 (+0.71%)
At close: 03:30PM KST
Full screen
Previous Close211,500.00
Bid213,000.00 x 0
Ask213,500.00 x 0
Day's Range206,500.00 - 214,000.00
52 Week Range193,500.00 - 395,588.25
Avg. Volume791,988
Market Cap29.049T
Beta (5Y Monthly)0.71
PE Ratio (TTM)N/A
Earnings DateFeb. 21, 2022 - Feb. 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec. 27, 2012
1y Target Est283,267.00
  • Reuters

    UPDATE 2-EU regulator backs COVID-19 drugs from Regeneron-Roche, Celltrion

    Europe's drug regulator has recommended two COVID-19 antibody therapies - one from American-Swiss partners Regeneron-Roche and another from South Korea's Celltrion, as the region builds up its defence against surging cases. Approval by the European Commission would mark the first for any COVID-19 treatment on the continent since Gilead's remdesivir last year Reuters reported earlier this week that the European Medicines Agency's (EMA) endorsement of the two drugs was imminent.

  • Business Wire

    Celltrion Awarded up to $626 Million From the Department of Defense to Supply COVID-19 Point-of-Care (POC) Rapid Antigen Test Kits

    INCHEON, South Korea, September 23, 2021--Celltrion is awarded up to USD 626 Million from the Department of Defense to supply COVID-19 Point-of-Care (POC) Rapid Antigen Test Kits.

  • Reuters

    U.S. government to buy point-of-care COVID-19 tests from Abbott, Celltrion -source

    The U.S. government has agreed to purchase point-of care COVID-19 tests from Abbott Laboratories and Celltrion Inc to ship to nursing homes and other high risk populations as part of its broader plan to purchase $2 billion in rapid coronavirus tests, a person familiar with the matter said on Tuesday. The federal government will purchase tests as needed and has agreed to spend up to $626 million in its agreement with Celltrion and $554.4 million in its deal with Abbott, the person said.